Unknown

Dataset Information

0

Low Percentage of Signal Regulatory Protein ?/?+ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients.


ABSTRACT: An important goal for personalized treatment is predicting response to a particular therapeutic. A drawback of biological treatment is immunogenicity and the development of antibodies directed against the drug [anti-drug antibodies (ADA)], which are associated with a poorer clinical outcome. Here we set out to identify a predictive biomarker that discriminates rheumatoid arthritis (RA) patients who are more likely to develop ADA in response to adalimumab, a human monoclonal antibody against tumor necrosis factor (TNF)?. By taking advantage of an immune-phenotyping platform, LEGENDScreen™, we measured the expression of 332 cell surface markers on B and T cells in a cross-sectional adalimumab-treated RA patient cohort with a defined ADA response. The analysis revealed seven differentially expressed markers (DEMs) between the ADA+ and ADA- patients. Validation of the DEMs in an independent prospective European cohort of adalimumab treated RA patients, revealed a significant and consistent reduced frequency of signal regulatory protein (SIRP)?/?-expressing memory B cells in ADA+ vs. ADA- RA patients. We also assessed the predictive value of SIRP?/? expression in a longitudinal RA cohort prior to the initiation of adalimumab treatment. We show that a frequency of < 9.4% of SIRP?/?-expressing memory B cells predicts patients that will develop ADA, and consequentially fail to respond to treatment, with a receiver operating characteristic (ROC) area under the curve (AUC) score of 0.92. Thus, measuring the frequency of SIRP?/?-expressing memory B cells in patients prior to adalimumab treatment may be clinically useful to identify a subgroup of active RA subjects who are going to develop an ADA response and not gain substantial clinical benefit from this treatment.

SUBMITTER: Magill L 

PROVIDER: S-EPMC6290031 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Low Percentage of Signal Regulatory Protein α/β<sup>+</sup> Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients.

Magill Laura L   Adriani Marsilio M   Berthou Véronique V   Chen Keguan K   Gleizes Aude A   Hacein-Bey-Abina Salima S   Hincelin-Mery Agnes A   Mariette Xavier X   Pallardy Marc M   Spindeldreher Sebastian S   Szely Natacha N   Isenberg David A DA   Manson Jessica J JJ   Jury Elizabeth C EC   Mauri Claudia C  

Frontiers in immunology 20181205


An important goal for personalized treatment is predicting response to a particular therapeutic. A drawback of biological treatment is immunogenicity and the development of antibodies directed against the drug [anti-drug antibodies (ADA)], which are associated with a poorer clinical outcome. Here we set out to identify a predictive biomarker that discriminates rheumatoid arthritis (RA) patients who are more likely to develop ADA in response to adalimumab, a human monoclonal antibody against tumo  ...[more]

Similar Datasets

| S-EPMC5088626 | biostudies-literature
2020-08-24 | GSE138747 | GEO
| S-EPMC8172642 | biostudies-literature
| EGAS00001007578 | EGA
| S-EPMC4309634 | biostudies-literature
2020-08-24 | GSE138746 | GEO
2020-08-24 | GSE138653 | GEO
| S-EPMC6097048 | biostudies-literature
| S-EPMC6099512 | biostudies-literature
| S-EPMC5623327 | biostudies-literature